ADAMIS PHARMACEUTICALS CORP (ADMP) 0.1853 -0.01 (-3.74%)
0.1853 -0.01 (-3.74%)
US00547W2089 - Common Stock - After market: 0.185 0 (-0.16%)
Fundamental Rating
Taking everything into account, ADMP scores 2 out of 10 in our fundamental rating. ADMP was compared to 257 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of ADMP have multiple concerns. ADMP is quite expensive at the moment. It does show a decent growth rate.
Profitability
Profitability Rating
ADMP has negative profitability rations, so we won't be analyzing them here.
ADMP's Return On Assets of -653.63% is worse than the rest of the industry. The industry average Return On Assets is -41.45%. 99% of the industry peers have a better Return On Assets.
ADMP has a Profit Margin of -1329.19%. This is below the industry average of -108.01%. 89% of the industry peers outperform ADMP.
The Piotroski-F score of ADMP is 3.00. This is a low score and indicates issues in the health and profitability of ADMP.
VS Industry
ROA (-653.63%) VS Industry: 1% outperformed.
-1,292.14
111.39
Profit Margin (-1329.19%) VS Industry: 11% outperformed.
-53,337.68
1,968.82
Valuation
Valuation Rating
With a price book ratio of 9.26, ADMP is valued correctly.
ADMP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ADMP is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
When comparing the price book ratio of ADMP to the average industry price book ratio of 1.43, ADMP is valued more expensive than its industry peers. 92% of the companies listed in the same industry are valued cheaper.
VS Industry
Price/Book (9.26) VS Industry: 8% outperformed.
305.58
0.10
Growth
Growth Rating
ADMP shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 58.49%, which is quite impressive.
ADMP is expected to show quite a strong growth in Earnings Per Share. In the coming 5 years, the EPS will grow by 12.40% yearly.
ADMP is expected to show quite a strong growth in Revenue. In the coming 5 years, the Revenue will grow by 16.64% yearly.
When comparing the Revenue growth rate of the last 5 years to the growth rate of the upcoming 5 years, we see that the growth is accelerating.
Looking at the last year, ADMP shows a very negative growth in Revenue. The Revenue has decreased by -15.56% in the last year.
ADMP shows a very negative growth in Revenue. Measured over the last 5 years, the Revenue has been decreasing by -19.34% yearly.
| Past | Future | ||||||
|---|---|---|---|---|---|---|---|
| 5Y | 3Y | 1Y | 1Y | 2Y | 3Y | 5Y | |
| EPS | N/A | N/A | 58.49% | 56.29% | 35.1% | 24.13% | 12.4% |
| Revenue | -19.34% | -47.3% | -15.56% | -45.73% | -0.9% | 8.68% | 16.64% |
Health
Health Rating
ADMP has a Current Ratio of 1.14. This is a normal value and indicates that ADMP is financially healthy and should not expect problems in meeting its short term obligations.
ADMP has a Quick Ratio of 1.01. This is a normal value and indicates that ADMP is financially healthy and should not expect problems in meeting its short term obligations.
The Debt to Equity ratio of ADMP is in line with the industry averages.
Compared to an average industry Current Ratio of 3.51, ADMP is worse placed to pay its short term obligations than its industry peers. 86% of its industry peers have a better Current Ratio.
Compared to an average industry Quick Ratio of 2.88, ADMP is worse placed to pay its short term obligations than its industry peers. 83% of its industry peers have a better Quick Ratio.
Based on the Altman-Z score of -48.67, we must say that ADMP is in the distress zone and has some risk of bankruptcy.
When comparing the Altman-Z score of ADMP to the average industry Altman-Z score of -0.53, ADMP is less financially healthy than its industry peers. 99% of its industry peers have a better Altman-Z score.
ADMP has a quite weak Piotroski-F score of 3.00. This indicates issues in the health and profitability of ADMP.
VS Industry
Debt/Equity (0) VS Industry: 54% outperformed.
59.36
0.00
Quick Ratio (1.01) VS Industry: 17% outperformed.
-2.73
76.82
Current Ratio (1.14) VS Industry: 14% outperformed.
0.09
76.82
Altman-Z (-48.67) VS Industry: 1% outperformed.
-231.44
114.17
Dividend
Dividend Rating
ADMP does not give a dividend.
ADAMIS PHARMACEUTICALS CORP0.1853
NASDAQ:ADMP (12/6/2022, 7:19:55 PM)-0.01 (-3.74%)
| GICS Sector | Health Care | ||
| GICS IndustryGroup | Pharmaceuticals, Biotechnology & Life Sciences | ||
| GICS Industry | Pharmaceuticals | ||
| Earnings (Last) | 11-14 2022-11-14/amc | Earnings (Next) | 03-29 2023-03-29 |
| Ins Owners | 0.67% | Inst Owners | 8.57% |
| Market Cap | 27.79M | Analysts | 43.33 |
| PE | N/A | Fwd PE | N/A |
| PEG (NY) | N/A | PEG (5Y) | N/A |
| P/S | 4.66 | P/B | 9.26 |
| EV/EBITDA | -0.47 | ||
| Dividend Yield | N/A | Dividend Growth | N/A |
| DP | N/A | Ex-Date | N/A |
| EPS 1Y | 58.49% | EPS 3Y | N/A |
| EPS 5Y | N/A | EPS growth Q2Q | 72.73% |
| EPS Next Y | 56.29% | EPS Next 2Y | 35.1% |
| EPS Next 3Y | 24.13% | EPS Next 5Y | 12.4% |
| Revenue growth 1Y | -15.56% | Revenue growth 3Y | -47.3% |
| Revenue growth 5Y | -19.34% | Revenue growth Q2Q | 98.13% |
| Revenue Next Year | -45.73% | Revenue Next 2Y | -0.9% |
| Revenue Next 3Y | 8.68% | Revenue Next 5Y | 16.64% |
| Current Ratio | 1.14 | Quick Ratio | 1.01 |
| Altman-Z | -48.67 | F-Score | 3 |
| Debt/Equity | 0 | WACC | 8.79% |
| ROIC/WACC | N/A | ||
| ROA | -653.63% | ROE | N/A |
| ROICexgc | N/A | ROIC | N/A |
| PM | -1329.19% | OM | -1016.99% |
| Asset Turnover | 0.49 | ||
Fundamental Stock Screener Links
Fundamental Stock Screener
Find stocks with similar Fundamental rating on the USA
Best Fundamental Competitors Stock Screener
Find the competitors with the best fundamentals on the USA
Best Valuation Competitors Stock Screener
Find the competitors with the best valuation on the USA
Best Dividend Competitors Stock Screener
Find the competitors with the best dividend on the USA